Logo

Iconix Wins EPA Contract for Chemogenomics-Based Toxicity Screens

Jan 06, 2005

NEW YORK, Jan. 6 (GenomeWeb News) - Iconix Pharmaceuticals has won a contract from the Environmental Protection Agency to screen chemicals for toxicity using its chemogenomics platform, the company said today.

 

Iconix, based in Mountain View, Calif., will use its DrugMatrix platform to work work with the EPA's Computational Toxicology Research Program to study the potential toxicity of five undisclosed chemicals.

 

DrugMatrix contains profiles of more than 650 chemical compounds, including information about gene expression, biological pathways, toxicology, and pharmacology.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.